Justin Chivinski practices in the area of corporate law. Mr. Chivinski is a 2013 graduate of Duke University School of Law and a graduate of the Pennsylvania State University.
· Represented Iroko Pharmaceuticals, a global specialty pharmaceutical company dedicated to advancing the science of responsible pain management, in securing $75 million in debt financing to support general business operations and the commercialization of Iroko's FDA-approved ZORVOLEX™ (diclofenac), a drug that uses iCeutica Inc.'s proprietary SoluMatrix Fine Particle Technology™ to both reduce the dosage of active ingredients ingested by the patient and accelerate the dissolution of the drug in the patient.
· Represented Alexar Therapeutics, Inc., a newly formed derm-focused pharmaceutical company, in connection with the sale of $21.5 million of Series A-1 and Series A-2 Preferred Stock to Third Point, New Science Ventures and Palo Alto, venture capital firms active in the pharmaceutical space, and the simultaneous closing of the purchase of the stock of Anayaderm, a development-stage pharmaceutical company.
· Represented a French media and sports management company in connection with the acquisition by its U.S. subsidiary of a golf events management company.
· Duane Morris LLP
- Associate, 2013-present